Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Director | June 04, 2026 | June 05, 2026 |
| Axsome Therapeutics, Inc.AXSM · Entity 2469 | Director | June 08, 2026 | June 11, 2026 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Director | May 06, 2021 | May 08, 2021 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-04 | Direct | 8,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 8,000 · Balance 8,000 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.
Axsome Therapeutics, Inc.
Report date June 08, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 829 |
Ending reported balance
After 2026-06-10 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-06-08 · Exercise / conversion · Acquired 1,429 · Balance 1,429 F2: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant. F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Row 2 · 2026-06-09 · Sale · Disposed 300 · Balance 1,129 F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. Row 3 · 2026-06-10 · Sale · Disposed 300 · Balance 829 F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-08 · Exercise / conversion · Disposed 1,429 · Balance 0 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.
F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.
Zymeworks BC Inc.
Report date May 06, 2021 · Filed May 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.49 · Expires 2031-05-05 | Direct | 9,000 |
Reported balance
After 2021-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-06 · Grant · Acquired 9,000 · Balance 9,000 F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 11,500 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 11,500 · Balance 11,500 F1: Stock options vest on January 12, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-01-12 | Direct | 7,700 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 7,700 · Balance 7,700 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3: RSUs vest on January 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on January 12, 2027.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3: RSUs vest on January 12, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ELI LILLY & Co
Report date April 13, 2018 · Filed February 01, 2019 · Amendment
Section 16 reporting ended · disclosed 2019-02-01. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,685 |
Reported balance
After 2018-04-16 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-04-16 · Sale · Disposed 17,379 · Balance 40,685 F1: This amendment is being filed to correct the total holdings held by the reporting person following the transaction reported on the original Form 4 filed on April 17, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed to correct the total holdings held by the reporting person following the transaction reported on the original Form 4 filed on April 17, 2018.
Horizon Therapeutics Public Ltd Co
Report date October 06, 2023 · Filed October 06, 2023
Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 1
1 source rowRow 1 · 2023-10-06 · Disposition to issuer · Disposed 9,345 · Balance 0 F1: 7,311 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly. F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2023-10-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-10-06 · Disposition to issuer · Disposed 9,306 · Balance 0 F1: 7,311 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly. F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-07-27 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-10-06 · Disposition to issuer · Disposed 4,016 · Balance 0 F3: Each RSU (as defined in footnote 5 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F5: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration. F4: The Ordinary Shares subject to the RSUs vest on July 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: 7,311 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly.
F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
F3: Each RSU (as defined in footnote 5 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.
F4: The Ordinary Shares subject to the RSUs vest on July 27, 2024.
F5: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2018 Filed Apr 17, 2018 19:29 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,165 | $80.14 | $413,923.10 |
DisclosureSEC source: 0000059478-18-000123 · wf-form4_152399337145959.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,652 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.00 to $80.41. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:24 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000068 · wf-form4_151787307587534.xml · derivative · entry 6 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:24 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 9,533 | $81.45 | $776,462.85 |
DisclosureSEC source: 0000059478-18-000068 · wf-form4_151787307587534.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,817 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:24 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000068 · wf-form4_151787307587534.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:06 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 11,111 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000042 · wf-form4_151743996649400.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,111 Underlying: Common Stock · 11,111 shares Expires 2019-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:06 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,363 | $87.60 | $119,398.80 |
DisclosureSEC source: 0000059478-18-000042 · wf-form4_151743996649400.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 14,872 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:06 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 12,412 | $87.60 | $1,087,291.20 |
DisclosureSEC source: 0000059478-18-000042 · wf-form4_151743996649400.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,436 Read SEC document |
| January 29, 2018 Filed Feb 5, 2018 23:27 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,365 | $87.60 | $119,574.00 |
DisclosureSEC source: 0000059478-18-000070 · wf-form4a_151787325808208.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 14,874 F1 · shares: This amendment is being filed to correctly report the amount disposed in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount disposed in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F2 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 22:17 UTC | ASSEMBLY BIOSCIENCES, INC. ASBM · Entity 5216 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $42.61 | $0.00 |
DisclosureSEC source: 0001144204-17-064152 · tv481596_form4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-12-14 F1 · derivative.exercise_date: The shares of common stock underlying the option will vest in equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 22:32 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 36,585 | $86.18 | $3,152,895.30 |
DisclosureSEC source: 0000059478-17-000239 · wf-form4_151251316307730.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,885 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.39 to $86.71. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 03, 2017 Filed Dec 5, 2017 22:32 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 15,861 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000239 · wf-form4_151251316307730.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,024 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:08 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 9,732 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000074 · wf-form4_148615248786775.xml · derivative · entry 6 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,732 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:08 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 4,570 | $77.03 | $352,027.10 |
DisclosureSEC source: 0000059478-17-000074 · wf-form4_148615248786775.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,470 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:08 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 9,732 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000074 · wf-form4_148615248786775.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:13 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000041 · wf-form4_148590438218792.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,326 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:13 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 2,030 | $75.38 | $153,021.40 |
DisclosureSEC source: 0000059478-17-000041 · wf-form4_148590438218792.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 13,509 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:13 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 19,243 | $75.38 | $1,450,537.34 |
DisclosureSEC source: 0000059478-17-000041 · wf-form4_148590438218792.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,308 Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 19:40 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 1,149 | $72.68 | $83,509.32 |
DisclosureSEC source: 0000059478-16-000485 · wf-form4_148217643981276.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 11,479 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 19:40 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 737 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000485 · wf-form4_148217643981276.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,065 Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 19:40 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 19,093 | $72.65 | $1,387,106.45 |
DisclosureSEC source: 0000059478-16-000485 · wf-form4_148217643981276.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,802 Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 19:29 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 4,584 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000477 · wf-form4_148096617016804.xml · derivative · entry 6 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 0 Underlying: Common Stock · 4,584 shares Expires 2016-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 19:29 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 1,489 | $67.12 | $99,941.68 |
DisclosureSEC source: 0000059478-16-000477 · wf-form4_148096617016804.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 12,628 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 19:29 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 4,584 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000477 · wf-form4_148096617016804.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 14,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 18:58 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 9,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000302 · wf-form4_145452587491047.xml · derivative · entry 6 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,843 shares Expires 2016-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 18:58 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 4,629 | $79.10 | $366,153.90 |
DisclosureSEC source: 0000059478-16-000302 · wf-form4_145452587491047.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,895 Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 18:58 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 9,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000302 · wf-form4_145452587491047.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2016 Filed Jan 28, 2016 23:42 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 9,732 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000267 · wf-form4_145402454064285.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,732 Underlying: Common Stock · 9,732 shares Expires 2017-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2016 Filed Jan 28, 2016 23:42 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,149 | $81.96 | $94,172.04 |
DisclosureSEC source: 0000059478-16-000267 · wf-form4_145402454064285.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 9,533 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 26, 2016 Filed Jan 28, 2016 23:42 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 19,093 | $81.96 | $1,564,862.28 |
DisclosureSEC source: 0000059478-16-000267 · wf-form4_145402454064285.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,681 Read SEC document |
| November 06, 2015 Filed Jan 25, 2016 20:39 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000241 · wf-form5_145375438646216.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 8,384 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| July 28, 2015 Filed Jul 29, 2015 17:30 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 25,000 | $84.96 | $2,124,000.00 |
DisclosureSEC source: 0000059478-15-000161 · wf-form4_143819099484130.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,728 Read SEC document |
| March 04, 2015 Filed Jan 25, 2016 20:39 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 140 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000241 · wf-form5_145375438646216.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,588 Read SEC document |
| February 11, 2015 Filed Feb 12, 2015 21:53 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 2/06 (right to buy) · Derivative | 9,036 | $0.00 Strike: $56.18 | $0.00 |
DisclosureSEC source: 0000059478-15-000089 · wf-form4_142377800130815.xml · derivative · entry 6 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,036 shares Expires 2016-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2015 Filed Feb 12, 2015 21:53 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 8,065 | $70.50 | $568,582.50 |
DisclosureSEC source: 0000059478-15-000089 · wf-form4_142377800130815.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,728 Read SEC document |
| February 11, 2015 Filed Feb 12, 2015 21:53 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 9,036 | $56.18 | $507,642.48 |
DisclosureSEC source: 0000059478-15-000089 · wf-form4_142377800130815.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 21:01 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 12,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000060 · wf-form4_142299728909233.xml · derivative · entry 6 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,591 shares Expires 2015-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 21:01 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 5,921 | $72.00 | $426,312.00 |
DisclosureSEC source: 0000059478-15-000060 · wf-form4_142299728909233.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,487 Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 21:01 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 12,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000060 · wf-form4_142299728909233.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:36 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 9,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000032 · wf-form4_142265738408482.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,843 Underlying: Common Stock · 9,843 shares Expires 2016-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:36 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,174 | $70.97 | $83,318.78 |
DisclosureSEC source: 0000059478-15-000032 · wf-form4_142265738408482.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 8,984 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:36 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 27,287 | $70.97 | $1,936,558.39 |
DisclosureSEC source: 0000059478-15-000032 · wf-form4_142265738408482.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,817 Read SEC document |
| December 04, 2014 Filed Feb 4, 2015 18:58 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 730 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000072 · wf-form5_142307632673641.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,757 Read SEC document |
| August 13, 2014 Filed Aug 15, 2014 17:29 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 2/05 (right to buy) · Derivative | 8,521 | $0.00 Strike: $55.65 | $0.00 |
DisclosureSEC source: 0000059478-14-000141 · wf-form4_140812375788362.xml · derivative · entry 6 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,521 shares Expires 2015-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2014 Filed Aug 15, 2014 17:29 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 7,789 | $60.88 | $474,194.32 |
DisclosureSEC source: 0000059478-14-000141 · wf-form4_140812375788362.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,530 Read SEC document |
| August 13, 2014 Filed Aug 15, 2014 17:29 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 8,521 | $55.65 | $474,193.65 |
DisclosureSEC source: 0000059478-14-000141 · wf-form4_140812375788362.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 20:32 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 2/06 (right to buy) · Derivative | 1,175 | $0.00 Strike: $56.18 | $0.00 |
DisclosureSEC source: 0000059478-14-000135 · wf-form4_140675226363198.xml · derivative · entry 8 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 0 Underlying: Common Stock · 1,175 shares Expires 2016-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 20:32 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 2/05 (right to buy) · Derivative | 1,065 | $0.00 Strike: $55.65 | $0.00 |
DisclosureSEC source: 0000059478-14-000135 · wf-form4_140675226363198.xml · derivative · entry 7 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 0 Underlying: Common Stock · 1,065 shares Expires 2015-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 20:32 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 2,065 | $63.30 | $130,714.50 |
DisclosureSEC source: 0000059478-14-000135 · wf-form4_140675226363198.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 7,810 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 20:32 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 1,175 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000135 · wf-form4_140675226363198.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 9,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 20:32 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 1,065 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000135 · wf-form4_140675226363198.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 8,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.